Celon Pharma S.A (CLN) Fair Value & Analysis
Healthcare · PL · Market cap 1.1B PLN
Fair value as of: Jun 24, 2026
From 13 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 8.12 PLN to 6.86 PLN (−15.5%) since Jun 23, 2026. Share price −3.2% over the past month.
Price vs Fair Value (12 months)
12‑month range 18.95 PLN – 24.27 PLN · fair‑value band 5.10 PLN – 8.61 PLN · the 19.98 PLN price screens above the 6.86 PLN fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Celon Pharma S.A (CLN) currently trades at 19.98 PLN, while our model-based Fair Value estimate is 6.86 PLN — implying the stock looks roughly 65.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Celon Pharma S.A generated revenue of 226M PLN at a net margin of -54.3%. Revenue grew 24.9% year over year. It earns a return on equity of -27.0%. Net debt stands at 8.6M PLN. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.
Revenue & earnings trend
FY2020 – FY2025 · reported fiscal years
Celon Pharma S.A reported revenue of 177M PLN in FY2024 versus 157M PLN in FY2020, a compound +2.9%/yr. Reported net income was −79.4M PLN in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Celon Pharma S.A (CLN) undervalued?
What is the fair value of CLN?
What is the quality score of CLN?
What is the revenue of Celon Pharma S.A (CLN)?
What is the net profit margin of CLN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.